Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy

Current Drug Discovery Technologies

Volumn 6, Issue 1, 2009, Pages 72-81

  Van Der Speeten, Kurt ^a   Stuart, Oswald Anthony ^b   Sugarbaker, Paul H ^b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

5 fluorouracil; Appendiceal cancer; Colorectal cancer; Doxorubicin; Intraperitoneal chemotherapy; Mitomycin C; Ovarian cancer; Peritoneal mesothelioma; Peritoneal plasma barrier

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MELPHALAN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PEMETREXED;

APPENDIX CANCER; AREA UNDER THE CURVE; CARCINOMATOSIS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; HUMAN; OVARY CANCER; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; TISSUE DISTRIBUTION;

EID: 62149086644     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309787581084     Document Type: Review

References (97)

1. Jayne D.G., Fook S., Loi C., Seow-Choen F.: Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 89, 1545-1550, (2002).
2. Brodsky J.T., Cohen A.M.: Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis. Colon Rectum 34(8), 723-728, (1991).
3. Chu D.Z., Lang N.P., Thompson C., Osteen P.K., Westbrook K.C.: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63(2), 364-367, (1989).
4. Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., Fontaumard E., Brachet A., et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88(2), 358-363, (2000).
5. De Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947, (2000).
6. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041-1047, (2000).
7. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342, (2004).
8. Spratt J.S., Adcock R.A., Muskovin M., Sherrill W., McKeown J.: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 40(2), 256-260, (1980).
9. Koga S., Shimizu N., Maeta M., Hamazoe R., Izumi A.: Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system). Gan. To. Kagaku. Ryoho. 10(2), 358-365, (1983).
10. Speyer J.L., Meyers C.E.: The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res. 74, 264-269, (1980).
11. Sugarbaker PH. Peritonectomy procedures. Surg. Oncol. Clin. N. Am. 12(3), 703-727, (2003).
12. Glehen O., Mithieux F., Osinsky D., Beaujard A.C., Freyer G., Guertsch P., Francois Y., Peyrat P., et al.: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J. Clin. Oncol. 21(5), 799-806, (2003).
13. Elias D., Blot F., El Otmany A., Antoun S., Lasser P., Boige V., Rougier P., Ducreux M.: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92(1), 71-76, (2001).
14. Glehen O., Gilly F.N., Sugarbaker P.H.: New perspectives in the management of colorectal cancer: what about peritoneal carcinomatosis? Scan J. Surg. 92(2), 178-179, (2003).
15. Shen P., Levine E.A., Hall J., Case D., Russell G., Fleming R., McQuellon R., Geisinger K.R., et al.: Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch. Surg. 138(1), 26-33, (2003).
16. Pestieau S.R., Sugarbaker P.H.: Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis. Colon Rectum 43(10), 1341-1346, (2000).
17. Witkamp A.J., De Bree E., Kaag M.M., Boot H., Beijnen J.H., Van Sloothen G.W., Van Coevorden F., Zoetmulder F.A.: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur. J. Cancer 37(8), 979-984, (2001).
18. Verwaal V.J., Van Ruth S., De Bree E., Van Sloothen G.W., Van Tinteren H., Boot H., Zoetmulder F.A.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21(20), 3737-3743, (2003).
19. Glehen O., Kwiatkowski F., Sugarbaker P.H., Elias D., Levine E.A., De Simone M., Barone R., Yonemura Y.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J. Clin. Oncol. 22(16), 3284-3292, (2004).
20. Yan T.D., Black D., Sugarbaker P.H., Zhu J., Yonemura Y., Petrou G., Morris D.L.: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann. Surg. Oncol. 14(10), 2702-2713, (2007).
21. Bijelic L., Jonson A., Sugarbaker P.H.: Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann. Oncol. 18(12), 1943-1950, (2007).
22. Yan T.D., Welch L., Black D., Sugarbaker P.H.: A systematic review of the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 18(5), 827-834, (2007).
23. Yan T.D., Black D., Savady R., Sugarbaker P.H.: A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann. Surg. Oncol. 14(2), 484-492, (2007).
24. Yan T.D., Black D., Savady R., Sugarbaker P.H.: Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J. Clin. Oncol. 24(24), 4011-4019, (2006).
25. Baron M.A.: Structure of the intestinal peritoneum in man. Am. J. Anat. 69, 439-497, (1941).
26. Dobbie J.W.: Ultrastructure and pathology of the peritoneum in peritoneal dialysis. In Textbook of peritoneal dialysis, Gokal R., Nolph K., Ed.; Kluwer Academic: Dordrecht, pp. 17-45, (1994).
27. Sugarbaker P.H.: Peritoneum as the first line of defense in carcinomatosis. J. Surg. Oncol. 95(2), 93-96, (2007).
28. Oosterling S.J., van der Bij G.J., van Egmond M., van der Sijp J.R.M.: Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur. J. Surg. Oncol. 31(1), 29-37, (2005).
29. Flessner M.F., Henegar J., Bigler S., Genous L.: Is the peritoneum a significant transport barrier in peritoneal dialysis? Perit. Dial. Int. 23(6), 542-549, (2003).
30. De Lima Vazquez V., Stuart O.A., Mohamed F., Sugarbaker P.H.: Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother. Pharmacol. 52(2), 108-112, (2003).
31. Jacquet P., Averbach A., Stephens A.D., Stuart O.A., Chang D., Sugarbaker P.H.: Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies. Oncology 55(2), 130-138, (1998).
32. Stelin G., Rippe B.: A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int. 38(3), 465-472, (1990).
33. Flessner M.F.: The transport barrier in intraperitoneal therapy. Am. J. Physiol. Renal Physiol. 288, 433-442, (2005).
34. Dedrick R.L., Myers C.E., Bungay P.M., De Vita V.T.: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 62(1), 1-11, (1978).
35. Sugarbaker P.H., Mora J.T., Carmignani P., Stuart O.A., Yoo D.: Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10(2), 112-122, (2005).
36. Dedrick R.L., Flessner M.F.: Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J. Natl. Cancer Inst. 89(7), 480-487, (1997).
37. Dedrick R.L., Flessner M.F., Collins J.M., Schultz J.S.: Is the peritoneum a membrane? Am. Soc. Artif. Internal Organs J. 5, 1-8, (1982).
38. Los G., Mutsaers P.H., Lenglet W.J., Baldew G.S., McVie J.G.: Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother. Pharmacol. 25(6), 389-394, (1990).
39. Los G., Verdegaal E.M., Mutsaers P.H., McVie J.G.: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28(3), 159-165, (1991).
40. Ozols R.F., Locker G.Y., Doroshow J.H., Grotzinger K.R., Myers C.E., Young R.C.: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 43(3), 3209-3214, (1979).
41. Sticca R.P., Dach B.W.: Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg. Oncol. Clin. N. Am. 12(3), 689-701, (2003).
42. Dahl O., Dalene R., Schem B.C., Mella O.: Status of clinical hyperthermia. Acta Oncol. 38, 863-873, (1999).
43. Lepock J.R.: How do cells respond to their thermal environment? Int. J. Hyperthermia 21(8), 681-687, (2005).
44. Hahn G.M., Braun J., Har-Kedar I.: Thermochemotherapy: synergism between hyperthermia (42-43°) and adriamycin ( or bleomycin ) in mammalian cell inactivation. Proc. Nat. Acad. Sci. 72(3), 937-940, (1975).
45. Kusumoto T., Holden S.A., Teicher B.A.: Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int. J. Hyperthermia 11(4), 575-586, (1995).
46. Barlogie B., Corry P.M., Drewinko B.: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and Mitomycin C. Cancer Res. 40(4), 1165-1168, (1980).
47. Urano M., Ling C.C.: Thermal enhancement of melphalan and oxaliplatin cytology in vitro. Int. J. Hyperthermia 18(4), 307-315, (2002).
48. Mohamed F., Marchettini P., Stuart O.A., Urano M., Sugarbaker P.H.: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann. Surg. Oncol. 10(4), 463-468, (2003).
49. Benoit L., Duvillard C., Rat P., Chauffert B.: Effets de la température intra-abdominale sur la diffusion tissulaire et tumorale du cisplatine intrapéritonéal dans un modèle de carcinose péritonéale chez le rat. Chirurgie 124(4), 375-379, (1999).
50. Jacquet P., Averbach A., Stuart O.A., Chang D., Sugarbaker P.H.: Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother. Pharmacol. 41(2), 147-154, (1998).
51. Esquis P., Consolo D., Magnin G., Pointaire P., Moretto P., Ynsa M.D., Beltramo J.L., Drogoul C, et al.: High intraabdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental carcinomatosis. Ann. Surg. 244(1), 106-112, (2006).
52. Jacquet P., Stuart O.A., Chang D., Sugarbaker P.H.: Effect of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 7(5), 596-603, (1996).
53. Garofalo A., Valle M., Garcia J., Sugarbaker P.H.: Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur. J. Surg. Oncol. 32(6), 682-685, (2006).
54. Facchiano E., Scaringi S., Kianmanesh R., Sabate J.M., Castel B., Flamant Y., Coffin B., Msika S.: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur. J. Surg. Oncol. 34(2), 154-158, (2008).
55. Pestieau S.R., Schnake K.J., Stuart O.A., Sugarbaker P.H.: Impact of carrier solutions on the pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 47(3), 269-276, (2001).
56. Mohamed F., Marchettini P., Stuart O.A., Sugarbaker P.H.: Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother. Pharmacol. 52(5), 405-410, (2003).
57. Mohamed F, Sugarbaker P.H.: Carrier solutions for intraperitoneal chemotherapy. Surg. Oncol. Clin. N. Am. 12(3), 813-824, (2003).
58. Elias D., El Otmany A., Bonnay M., Paci A., Ducreux M., Antouns S., Lasser P., Laurent S., et al.: Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 63(4), 346-352, (2002).
59. Keshaviah P., Emerson P.F., Vonesh E.F., Brandes J.C.: Relationship between body size, fill volume and mass transfer area coefficient in peritoneal dialysis. J. Am. Soc. Nephrol. 4(10), 1820-1826, (1994).
60. Elias D.M., Sideris L.: Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg. Oncol. Clin. N. Am. 12(3), 755-769, (2003).
61. Sugarbaker P.H., Stuart O.A., Carmignani C.P.: Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother. Pharmacol. 57(5), 703-708, (2006).
62. Chauffert B., Favoulet P., Polycarpe E., Duvillard C., Beltramo J.L., Bichat F., Rat P., Genne P.: Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Surg. Oncol. Clin. N. Am. 12(3), 835-848, (2003).
63. Ensminger W.D., Gyves J.W.: Regional chemotherapy of neoplastic diseases. Pharmacol. Ther. 21(2), 277-293, (1983).
64. Favoulet P., Magnin G., Guilland J.C., Beltramo J.L. Osmak L., Benoit L., Rat P., Douvier S., et al.: Preclinical study of epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis. Eur. J. Surg. Oncol. 27(1), 59-64, (2001).
65. Molucon-Chabrot C., Isambert N., Benoit L., Zanetta S., Fraisse J., Guilland J.C., Royer B., Monin-Baroille P., et al.: Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs 17(10), 1211-1217, (2006).
66. Lidner P., Heath D., Howell S., Naredi P., Hafstrom L.: Vasopressin modulation of peritoneal, lymphatic and plasma drug exposure following intraperitoneal administration. Clin. Cancer Res. 2(2), 311-317, (1996).
67. Rubin J., Clawson M., Planch A., Jones Q.: Measurements of peritoneal surface area in man and rat. Am. J. Med. Sci. 295(5), 453-458, (1988).
68. Chagnac A., Herskovitz P., Weinstein T., Elyashiv S., Hirsh J., Hammel I., Gafter U.: The peritoneal membrane in peritoneal dialysis patients: estimation of its functional surface area by applying stereologic methods to computerized tomography scans. J. Am. Soc. Nephrol. 10(2), 342-346, (1999).
69. Rossi C.R., Deraco M., De Simone M., Mocellin S., Pilati P., Foletto M., Cavaliere F., Kusamura S.: Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 11(4), 1943-1950, (2004).
70. Baratti D., Kusamura S., Martinetti A., Seregni E., Laterza B., Oliva D.G., Deraco M.: Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 14(8), 2300-2308, (2007).
71. Glehen O., Schreiber V., Cotte E., Sayag-Beaujard A.C., Osinsky D., Freyer G., Francois Y., Vignal J.: Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch. Surg. 139(1), 20-26, (2004).
72. Gilly F.N., Carry P.Y., Sayag A.C., Brachet A., Panteix G., Salle B., Bienvenu J., Burgard G.: Regional chemotherapy (with mitomycin C) and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41(2), 124-129, (1994).
73. Fujimoto S., Shrestha R.D., Kokobun M., Kobayashi K., Kiuchi S., Konno C., Ohta M., Takahashi M., et al.: Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann. Surg. 212(5), 592-596, (1990).
74. Fujimura T., Yonemura Y., Fushida S., Urade M., Takegawa S., Kamata T., Sugiyama K., Hasegawa H.: Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65(1), 65-71, (1990).
75. Elias D., Antoun S., Raynard B., Puizillout J.M., Sabourin J.C., Ducreux M., Lasser P.: Treatment of peritoneal carcinomatosis using complete excision and intraperitoneal chemohyperthermia. A phase I-II study defining the best technical procedures. Chirurgie 124(4), 380-389, (1999).
76. Elias D., Antoun S., Goharin A., Otmany A.E., Puizillout J.M., Lasser P.: Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int. J. Surg. Investig. 1(5), 431-439, (2000).
77. Sugarbaker P.H.: An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J. Surg. Oncol. 92(2), 142-146, (2005).
78. Guerbet M., Goulle J.P., Lubrano J.: Evaluation of the risk of contamination of surgical personnel by vaporization of Oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy. Eur. J. Surg. Oncol. 33(5), 623-626, (2007).
79. Stuart O.A., Stephens A.D., Welch L., Sugarbaker P.H.: Safety monitoring of the coliseum technique for heated intraoperative chemotherapy with mitomycin C. Ann. Surg. Oncol. 9(2), 186-191, (2002).
80. Schmid K., Boettcher M.I., Pelz J.O., Meyer T., Korinth G., Angerer J., Drexler H.: Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with mitomycin C. Eur. J. Surg. Oncol. 32(10), 1222-1225, (2006).
81. Yonemura Y., Bandou E., Sawa T., Yoshimitsu Y., Endou Y., Sasaki T., Sugarbaker P.H.: Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur. J. Surg. Oncol. 32(6), 661-665, (2006).
82. Sugarbaker P.H.: Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res. 82, 317-325, (1996).
83. Zylberberg B., Dormont D., Janklewicz S., Darai E., Bretel J.J., Poncelet C., Guillet J.L., Madelenal P. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur. J. Gynaecol. Oncol. 22(1), 40-45, (2001).
84. Esquivel J., Vidal-Jove J., Steves M.A., Sugarbaker P.H.: Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 113(6), 631-636, (1993).
85. Sugarbaker P.H., Graves T., DeBruijn E.A., Cunliffe W.J., Mullins R.E., Hull W.E., Oliff L., Schlag P.: Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacologic studies. Cancer Res. 50(18), 5790-5794, (1990).
86. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354(1), 34-43, (2006).
87. Markman M., Bundy B.N, Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., Wadler S., Sickel J.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19(4), 1001-1007, (2001).
88. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., Franklin E.W., Clark-Pearson D.L.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335(26), 1950-1955, (1996).
89. Yan T.D., Bijelic L., Sugarbaker P.H.: Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann. Surg. Oncol. 14(8), 2289-2299, (2007).
90. Bijelic L., Yan T.D., Sugarbaker P.H.: Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann. Surg. Oncol. 14(8), 2281-2288, (2007).
91. Rippe B., Haraldsson B.: Transport of macromolecules across microvascular walls: the two-pore theory. Physiol. Rev. 74(1), 163-219, (1994).
92. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchillin V.P., Jain R.K.: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756, (1995).
93. Flessner M.F., Choi J., Credit K., Deverkadra R., Henderson K.: Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin. Cancer Res. 11(8), 3117-3125, (2005).
94. Nygren P., Fridborg H., Csoka K., Sundström C., de la Torre M., Kristensen J., Bergh J., Hagberg H., et al.: Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int. J. Cancer 56(5), 715-720, (1994).
95. Larsson R., Kristensen J., Sandberg C., Nygren P.: Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 50(2), 177-185, (1992).
96. Mahteme H., von Heideman A., Grundmark B., Tholander B., Pahlman L., Glimelius B., Larsson R., Graf W., et al. Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. Eur. J. Surg. Oncol. 34(5), 547-552, (2008).
97. Deraco M. Ed.; Consensus on the clinical application of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of cancer. J. Surg. Oncol. (special issue) [in press 2008].